|
|
||||||||
and
Light Chain Yeast Artificial Chromosomes1





*
Laboratory of Developmental Immunology and
Laboratory of Molecular Recognition, The Babraham Institute, Babraham, Cambridge, United Kingdom; and
Laboratory of Molecular Biology, Medical Research Council, Cambridge, United Kingdom
We have produced mice that carry the human Ig heavy (IgH) and both
and
light chain transloci in a background in which the
endogenous IgH and
loci have been inactivated. The B lymphocyte
population in these translocus mice is restored to about one-third of
normal levels, with preferential (3:1) expression of human
over
human
. Human IgM is found in the serum at levels between 50 and 400
µg/ml and is elevated following immunization. This primary human Ab
repertoire is sufficient to yield diverse Ag-specific responses as
judged by analysis of mAbs. The use of DH and J segments is
similar to that seen in human B cells, with an analogous pattern of N
nucleotide insertion. Maturation of the response is accompanied by
somatic hypermutation, which is particularly effective in the light
chain transloci. These mice therefore allow the production of
Ag-specific repertoires of both IgM,
and IgM,
Abs and should
prove useful for the production of human mAbs for clinical
use.
This article has been cited by other articles:
![]() |
L. Mazari, M. Ouarzane, and M. Zouali Subversion of B lymphocyte tolerance by hydralazine, a potential mechanism for drug-induced lupus PNAS, April 10, 2007; 104(15): 6317 - 6322. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. C. Sheppard, S. L. Davies, S. A. Jeffs, S. M. Vieira, and Q. J. Sattentau Production and Characterization of High-Affinity Human Monoclonal Antibodies to Human Immunodeficiency Virus Type 1 Envelope Glycoproteins in a Mouse Model Expressing Human Immunoglobulins Clin. Vaccine Immunol., February 1, 2007; 14(2): 157 - 167. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Viau, N. S. Longo, P. E. Lipsky, and M. Zouali Staphylococcal Protein A Deletes B-1a and Marginal Zone B Lymphocytes Expressing Human Immunoglobulins: An Immune Evasion Mechanism J. Immunol., December 1, 2005; 175(11): 7719 - 7727. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Tzipori, A. Sheoran, D. Akiyoshi, A. Donohue-Rolfe, and H. Trachtman Antibody Therapy in the Management of Shiga Toxin-Induced Hemolytic Uremic Syndrome Clin. Microbiol. Rev., October 1, 2004; 17(4): 926 - 941. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Viau, N. S. Longo, P. E. Lipsky, L. Bjorck, and M. Zouali Specific In Vivo Deletion of B-Cell Subpopulations Expressing Human Immunoglobulins by the B-Cell Superantigen Protein L Infect. Immun., June 1, 2004; 72(6): 3515 - 3523. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |